Founded in 2016 in São Paulo – Brazil, Biotimize has the mission of transforming lives through biotechnology, enabling ideas, treatments, and dreams to become reality. Biotimize works to develop new approaches to create a scenario where it is possible to democratize access to science and healing and create a positive impact on people.
Through the Biotechnology as a Service (BTaaS) model, we provide biotechnology and bioprocess engineering-based services to global companies or institutions. The solutions are of a personalized nature and can range from advisory support in projects developed by the client to the complete development of a product by our team.
We are able to follow all the necessary steps to obtain biopharmaceuticals for pre-clinical studies. In doing so, we can speed up the arrival of new technologies (from both mammalian cells and microorganisms) to the market based on (under OECD GLP certification):
• Cell line development (vector design; transient transfection; streamlined CLD process; final clones with expected quality and expression levels; RCB generation)
• Process development and optimization (media and feed development; clone evaluation in shake flasks; PD in bioreactors 600 mL – 4L; harvest/clarification; chromatography – Protein A, AEX, CEX, IMAC, HIC, Mixed model; viral inactivation; formulation; sterile filtration; stability)
• Analytical and QC testing (Title – ELISA, Protein A, Bradford, A280; PQ – CEX, SES; Purity – SDS-Page; endotoxin; HCP; HCD; ELISA)
• Non-GMP production (production of up to 4L of transient expression or stable pools/clones for tox studies; low endotoxin purification)
• Bioprocess technical-economic analysis
Through the Biotechnology as a Service (BTaaS) model, we provide biotechnology and bioprocess engineering-based services to global companies or institutions. The solutions are of a personalized nature and can range from advisory support in projects developed by the client to the complete development of a product by our team.
We are able to follow all the necessary steps to obtain biopharmaceuticals for pre-clinical studies. In doing so, we can speed up the arrival of new technologies (from both mammalian cells and microorganisms) to the market based on (under OECD GLP certification):
• Cell line development (vector design; transient transfection; streamlined CLD process; final clones with expected quality and expression levels; RCB generation)
• Process development and optimization (media and feed development; clone evaluation in shake flasks; PD in bioreactors 600 mL – 4L; harvest/clarification; chromatography – Protein A, AEX, CEX, IMAC, HIC, Mixed model; viral inactivation; formulation; sterile filtration; stability)
• Analytical and QC testing (Title – ELISA, Protein A, Bradford, A280; PQ – CEX, SES; Purity – SDS-Page; endotoxin; HCP; HCD; ELISA)
• Non-GMP production (production of up to 4L of transient expression or stable pools/clones for tox studies; low endotoxin purification)
• Bioprocess technical-economic analysis
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
